Last reviewed · How we verify
EGb761
EGb761 is a standardized Ginkgo biloba extract that enhances cerebral blood flow and provides neuroprotection through antioxidant and anti-inflammatory mechanisms.
EGb761 is a standardized Ginkgo biloba extract that enhances cerebral blood flow and provides neuroprotection through antioxidant and anti-inflammatory mechanisms. Used for Age-related cognitive decline, Dementia (including Alzheimer's disease), Cerebrovascular insufficiency.
At a glance
| Generic name | EGb761 |
|---|---|
| Also known as | Tanakan, Tanakan® |
| Sponsor | Ipsen |
| Drug class | Herbal extract / Neuroprotective agent |
| Modality | Small molecule |
| Therapeutic area | Neurology / Cognitive disorders |
| Phase | Phase 3 |
Mechanism of action
EGb761 works by improving microcirculation in the brain, reducing platelet aggregation, and scavenging free radicals. It also modulates neurotransmitter function and protects against ischemic injury, making it potentially beneficial for cognitive and cerebrovascular disorders.
Approved indications
- Age-related cognitive decline
- Dementia (including Alzheimer's disease)
- Cerebrovascular insufficiency
- Tinnitus
Common side effects
- Headache
- Gastrointestinal upset
- Dizziness
- Bleeding risk (minor)
Key clinical trials
- A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment (PHASE4)
- Ginkgo Active App-Based Exercise Training (NA)
- Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis (NA)
- Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin (NA)
- A Pilot Study to Examine the Effect of Egb761 on Plasma Biomarker Levels and on Cognitive Function in Patients With MCI (PHASE2)
- Gastrodin Acupoint Injection for Sensorineural Hearing Loss With Vertigo (NA)
- Modifiable Risk Factors for Non-traumatic Subconjunctival Hemorrhage
- Efficacy and Safety of Ginkgo Biloba Extract EGb761® in Patients With Diabetic Retinopathy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EGb761 CI brief — competitive landscape report
- EGb761 updates RSS · CI watch RSS
- Ipsen portfolio CI